Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Impact of testing for genetic markers on treatment selection and clinical outcomes among patients with chronic lymphocytic leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

DBDerrick van BeugeUniversidad San Carlos

Discussion

Loading...

Member takes

Overview

Retrospective cohort study shows genetic testing improves clinical outcomes in chronic lymphocytic leukemia patients, suggesting optimal treatment choices.

Key Points

  • To assess the impact of genetic marker testing on treatment selection and clinical outcomes in chronic lymphocytic leukemia (CLL).
  • Utilized the Flatiron Health Research Database for a retrospective cohort study.
  • Included adults diagnosed with chronic lymphocytic leukemia who started treatment between 2020-2024.
  • Evaluated outcomes based on testing for 17p deletion, TP53 mutation, and IGHV mutation.
  • Patients with genetic testing had improved time to next treatment compared to untested patients.
  • Median time to next treatment was 41.7 months for tested patients vs. 30 months for untested patients.
  • Testing was associated with a higher likelihood of receiving guideline-preferred novel therapies.

Cite This Study

Derrick van Beuge (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d85ehttps://doi.org/10.1182/blood-2025-3894
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world chronic lymphocytic leukemia (CLL)–specific biomarker testing patterns and frontline treatment patterns in patients with CLL/small lymphocytic lymphoma (SLL)2025
  2. 2A genomic analysis of patients with chronic lymphocytic leukemia treated with fixed duration therapy in a first-line setting in alberta, Canada2025
  3. 3Prognostic impact of genetic abnormalities in 536 first‐line chronic lymphocytic leukaemia patients without 17p deletion treated with chemoimmunotherapy in two prospective trials: Focus on IGHV‐mutated subgroups (a <scp>FILO</scp> study)2024 · 4 citations
  4. 4Real-world biomarker testing rates, targeted therapy use, and clinical outcomes in patients with advanced gastric or GEJ cancer in the United States.2026 · 1 citations
  5. 5Biallelic TP53 alterations predict poorer survival in Mantle Cell Lymphoma: Insights from a national real-world cohort high-touch project2025